All In Biotech

Drug Trial Radar · NCT04840927

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

An Open-Label, Single Center, Randomized, Pharmacoscintigraphic Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release Tablets Compared to an E7386 Immediate Release Tablet in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Nov 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 9, 2021

Primary completion

May 17, 2023

Study completion May 17, 2023

Sponsor

Lead sponsor
Eisai LimitedEisai
Sponsor type
Industry
First posted
Apr 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the pharmacokinetic (PK) profile of E7386 following oral administration of E7386 enteric coated TR prototype tablet formulations (TR1, TR2 and optional TR3) and to evaluate the relative bioavailability of E7386 TR tablets compared to E7386 IR reference tablet.

Conditions

  • Healthy Volunteers

Interventions

  • E7386Drug

    Regimen A: 40 milligram (mg) IR Oral Tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax: Maximum Observed Plasma Concentration for E7386Time frame: Day 1: 0-48 hours post-dose
  2. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386Time frame: Day 1: 0-48 hours post-dose
  3. AUC (0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386Time frame: Day 1: 0-48 hours post-dose
  4. AUC (0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time for E7386Time frame: Day 1: 0-48 hours post-dose
  5. T1/2: Terminal Elimination Phase Half-life for E7386Time frame: Day 1: 0-48 hours post-dose
  6. CL/F: Apparent Total Clearance Following Extravascular Administration for E7386Time frame: Day 1: 0-48 hours post-dose
  7. Vz/F: Apparent Volume of Distribution at Terminal Phase for E7386Time frame: Day 1: 0-48 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.